The Next Generation Immune Checkpoint Inhibitors And Stimulators Market Is Projected To Grow At An Annualized Rate Of ~10.5%, Till 2030

>

The next generation immune checkpoint inhibitors and stimulators market is projected to grow at an annualized rate of ~10.5%, till 2030

Roots Analysis has done a detailed study on Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 180+ page report, which features 90+ figures and 85+ tables, please visit this link

 

Key Market Insights

  • More than 35 industry players claim to offer services for the identification, characterization and development of peptides and macrocycle-based pharmacological lead candidates
  • Several technology developers have made significant contributions in terms of developing novel platforms, based on a variety of innovative approaches, for the discovery of peptide-based drugs and macrocyclic molecules.
  • Service providers are expanding their capabilities in order to enhance their respective portfolios; display libraries have emerged the most popular platforms.
  • In recent years, a steady increase in partnership activity has been observed, resulting in the establishment of a variety of deals related to different types of peptides and macrocycles.
  • Drug developers are likely to continue to outsource discovery stage operations for therapeutic peptides and macrocyclic drugs in mid to long term, resulting in multi-billion growth for contract service providers.
  • Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html

 

Table of Contents

 

  1. PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Chapter Outlines

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

3.1.      Chapter Overview

3.2.      History of Peptide Drugs

3.3.      Structure of Peptides

3.4.      Major Classes of Peptides     

3.5.      Discovery Stages of Peptides

3.6.      Synthesis of Peptides

3.7.      Modification of Peptides

3.8.      Methods for Peptide Analysis

3.9.      Contract Research Organizations (CROs) in Peptides and Macrocycle Drug Discovery

3.10.     Key Factors in CRO Selection

3.11.     Risks and Challenges Associates with CROs

 

 

  1. MARKET LANDSCAPE OF SERVICE PROVIDERS

4.1.      Chapter Overview

4.2.      Peptides and Macrocycle Drug Discovery Service Providers: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Location of Headquarters

4.2.4.    Analysis by Drug Discovery Steps

4.2.5.    Analysis by Type of Peptides Discovered

4.2.6.    Analysis by Peptide Generation Methods Used

4.2.7.    Analysis by Peptide Modification Methods Used

4.2.8.    Analysis by Other Services Offered

 

  1. BENCHMARK ANALYSIS

5.1.      Chapter Overview

5.2.      Methodology

5.3.      Region-wise Benchmarking

5.3.1.    Europe, Peer Group I

5.3.2.    North America, Peer Group II

5.3.3.    Asia Pacific, Peer Group III

5.4.      Summary of Region-wise Benchmarking Analysis

 

5.5.       Company Size-wise Benchmarking

5.5.1.    Companies in Different Peer Groups

5.5.2.    Small Companies, Peer Group I

5.5.3.    Mid-Sized Companies, Peer Group II

5.5.4.    Large and Very Large Companies, Peer Group III

5.6.      Summary of Company-Size wise Benchmarking Analysis

 

  1. MARKET LANDSCAPE OF PLATFORM PROVIDERS

6.1.      Chapter Overview

6.2.      Peptides and Macrocycle Drug Discovery Platform Providers: Overall Market Landscape

6.2.1.    Analysis by Year of Establishment

6.2.2.    Analysis by Company Size

6.2.3.    Analysis by Location of Headquarters

6.2.4.    Analysis by Type of Peptides Discovered      

6.3.      2X2 Matrix

6.3.1.    Section Overview

6.3.2.    2X2 Matrix: An Overview

6.3.3.    Methodology and Scoring

6.3.4.    2X2 Matrix: Plotting the Information

6.3.5.    2X2 Matrix: Analyzing the Information

6.3.5.1. High / High Compartment

6.3.5.2. Low / High Compartment

 

  1. COMPANY PROFILES

7.1.      Chapter Overview

7.2.      Peptides and Macrocycle Drug Discovery Service Providers

7.2.1.    GenScript

7.2.1.1. Company Overview

7.2.1.2. Service Portfolio

7.2.1.3. Future Outlook

 

7.2.2.    JPT Peptide Technologies

  1. 2.2.1. Company Overview
  2. 2.2.2. Service Portfolio
  3. 2.2.3. Future Outlook

 

7.2.3.    IRBM

7.2.3.1. Company Overview

7.2.3.2. Service Portfolio

7.2.3.3. Future Outlook

 

7.2.4.    Pepscan

7.2.4.1. Company Overview

7.2.4.2. Service Portfolio

7.2.4.3. Future Outlook

 

7.3       Peptides and Macrocycle Drug Discovery Platform Providers

7.3.1.    Interprotein

7.3.1.1. Company Overview

7.3.1.2. Technology Overview

7.3.1.3. Future Outlook

 

7.3.2.    RA Pharmaceuticals

  1. 3.2.1. Company Overview
  2. 3.2.2. Technology Overview
  3. 3.2.3. Future Outlook

 

7.3.3.    Pepticom

7.3.3.1. Company Overview

7.3.3.2. Technology Overview

7.3.3.3. Future Outlook

 

7.3.4.    PeptiDream

7.3.4.1. Company Overview

7.3.4.2. Technology Overview

7.3.4.3. Financial Information

7.3.4.4. Future Outlook

           

7.3.5.    Creative Biolabs

7.3.5.1. Company Overview

7.3.5.2. Service Portfolio

7.3.5.3. Technology Overview

7.3.5.4. Future Outlook

 

7.3.6.    MeSCue-Janusys

7.3.6.1. Company Overview

7.3.6.2. Peptide Discovery Platform

7.3.6.3. Future Outlook

 

7.3.7.    Cyclenium Pharma

7.3.7.1. Company Overview

7.3.7.2. Technology Overview

7.3.7.3. Future Outlook

 

7.3.8.    Orbit Discovery

7.3.8.1. Company Overview

7.3.8.2. Technology Overview

7.3.8.3. Future Outlook

           

  1. PARTNERSHIPS

8.1.      Chapter Overview

8.2.      Partnership Models

8.3.      Peptides and Macrocycle Drug Discovery Services and Platforms Providers: List of Partnerships

8.3.1.    Analysis by Year of Partnerships

8.3.2.    Analysis by Type of Partnerships

8.3.3.    Analysis by Year and Type of Partnerships

8.3.4.    Analysis by Type of Peptides

8.3.5.    Analysis by Key Focus Areas

8.4.      Geographical Analysis

8.4.1.    Local and International Agreements

8.4.2.    Intercontinental and Intracontinental Agreements

8.5.      Most Active Players: Analysis by Number of Partnerships

 

  1. MARKET FORECAST AND OPPORTUNITY ANALYSIS

9.1.      Chapter Overview

9.2.      Key Assumptions and Forecast Methodology

9.3.      Overall Peptide Drug Discovery Outsourcing Services Market, 2020-2030

9.4.      Peptide Drug Discovery Outsourcing Services Market: Analysis by Type of Peptide, 2020, 2025 and 2030

9.4.1.    Peptide Drug Discovery Outsourcing Services Market for Synthetic Peptides, 2020-2030

9.4.2.    Peptide Drug Discovery Outsourcing Services Market for Biological Peptides, 2020-2030

 

9.5.      Peptide Drug Discovery Outsourcing Services Market: Analysis by Drug Discovery Steps, 2020, 2025 and 2030

9.5.1.    Peptide Drug Discovery Outsourcing Services Market for Target Validation, 2020-2030

9.5.2.    Peptide Drug Discovery Outsourcing Services Market for Hit Identification, 2020-2030

9.5.3.    Peptide Drug Discovery Outsourcing Services Market for Lead Generation, 2020-2030

9.5.4.    Peptide Drug Discovery Outsourcing Services Market for Lead Optimization, 2020-2030

9.6.      Peptide Drug Discovery Outsourcing Services Market: Analysis by Therapeutic Area, 2020, 2025 and 2030

9.6.1.    Peptide Drug Discovery Outsourcing Services Market for Oncological Disorders, 2020-2030

9.6.2.    Peptide Drug Discovery Outsourcing Services Market for Metabolic Disorders, 2020-2030

9.6.3.    Peptide Drug Discovery Outsourcing Services Market for Cardiovascular Disorders, 2020-2030

9.6.4.    Peptide Drug Discovery Outsourcing Services Market for Neurological Disorders, 2020-2030

9.6.5.    Peptide Drug Discovery Outsourcing Services Market for Genetic Disorders, 2020-2030

9.6.6.    Peptide Drug Discovery Outsourcing Services Market for Gastroenterological Disorders, 2020-2030

9.6.7.    Peptide Drug Discovery Outsourcing Services Market for Gynecological Disorders, 2020-2030

9.6.8.    Peptide Drug Discovery Outsourcing Services Market for Hematological Disorders, 2020-2030

9.6.9.    Peptide Drug Discovery Outsourcing Services Market for Ophthalmological Disorders, 2020-2030

9.6.10.  Peptide Drug Discovery Outsourcing Services Market for Endocrine Disorders, 2020-2030

9.6.11.  Peptide Drug Discovery Outsourcing Services Market for Infectious Diseases, 2020-2030

9.6.12.  Peptide Drug Discovery Outsourcing Services Market for Other Diseases, 2020-2030

 

9.7.      Peptide Drug Discovery Outsourcing Services Market: Analysis by Company Size, 2020, 2025 and 2030

9.7.1.    Peptide Drug Discovery Outsourcing Services Market for Small Companies, 2020-2030

9.7.2.    Peptide Drug Discovery Outsourcing Services Market for Mid-Sized Companies, 2020-2030

9.7.3.    Peptide Drug Discovery Outsourcing Services Market for Large Companies, 2020-2030

9.8.       Peptide Drug Discovery Outsourcing Services Market: Analysis by Geography, 2020-2030

9.8.1.    Peptide Drug Discovery Outsourcing Services Market in North America, 2020-2030

9.8.2.    Peptide Drug Discovery Outsourcing Services Market in Europe, 2020-2030

9.8.3.    Peptide Drug Discovery Outsourcing Services Market in Asia Pacific, 2020-2030

9.8.4.    Peptide Drug Discovery Outsourcing Services Market in Rest of the World, 2020-2030

 

  1. SWOT ANALYSIS

10.1.     Chapter Overview

10.2.     Strengths

10.3.     Weaknesses

10.4.     Opportunities

10.5.     Threats

10.6.     Concluding Remarks

 

  1. CONCLUSION

11.1.     Chapter Overview

11.2.     Key Takeaways

 

  1. EXECUTIVE INSIGHTS

12.1.     Chapter Overview

12.2      Cyclenium Pharma

12.2.1.  Company Snapshot

12.2.2.  Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)

12.3.     Oncodesign

12.3.1. Company Snapshot

12.2.2.  Jan Hoflack (Chief Scientific Officer, Head of Biotech Business Unit, Oncodesign)

  1. APPENDIX 1: LIST OF COMPANIES AND ORGANIZATIONS
  1. APPENDIX 2: TABULATED DATA

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Share:

Keywords: biotech,research,analysis,rootsanalysis

Comments

Other related blogs

The “Prefilled Syringe Fill / Finish Service Providers, 2020-2030” report features an extensive study of the current market

By : Roots Analysis

Key Inclusions A detailed review of the overall landscape of companies offering contract fill / f..


The prefilled syringe fill / finish services market is projected to grow at an annualized rate of over 10%, till 2030

By : Roots Analysis

Roots Analysis has done a detailed study on Prefilled Syringe Fill / Finish Services Market, 2020-20..


The prefilled syringe fill / finish services market is estimated to is estimated to reach close to USD 3 Billion by 2030

By : Roots Analysis

The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, h..